close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Advaxis, Inc. - Common Stock (OP:ADXS)

0.0846 UNCHANGED
Last Price Updated: 12:40 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Advaxis, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
From Immunome, Inc.
Via Business Wire
News headline image
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile 
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023 ↗
 
Via Benzinga
News headline image
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Poster will feature updated results from Phase 2 portion of RINGSIDE, evaluating AL102 in desmoid tumors 
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Inc. (OTC:ADXS) Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors
Ayala Pharmaceuticals Inc. (OTC:ADXS) Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors 
Via News Direct
News headline image
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ ↗
Ayala Pharmaceuticals Inc (NASDAQ: AYLA) and Advaxis Inc (OTC: ADXS) have announced a merger agreement.  
Via Benzinga
News headline image
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers BioCardia (NASDAQ:BCDA) shares ro... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Reshape Lifesciences (NASDAQ:RSLS... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Lannett (NYSE:LCI) shares rose 11.61... 
Via Benzinga
News headline image
6 of the Hottest Stocks to Pick Up for Less Than $1 ↗
These penny stocks are trading for under a dollar, but could change that in the coming months with their strong fundamentals. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers FibroGen (NASDAQ:FGEN) stock mov... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Stealth BioTherapeutics (NASDAQ: 
Via Benzinga
News headline image
72 Biggest Movers From Yesterday ↗
Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from its Phase 1b/2a trial evaluating its lead... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today